Skip to Content

Symfi Approval History

FDA Approved: Yes (First approved March 22, 2018)
Brand name: Symfi
Generic name: efavirenz, lamivudine and tenofovir disoproxil fumarate
Dosage form: Tablets
Company: Mylan Pharmaceuticals Inc.
Treatment for: HIV Infection

Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate) is a three-drug combination of a non-nucleoside reverse transcriptase inhibitor (efavirenz), and two nucleo(t)side reverse transcriptase inhibitors (lamivudine and tenofovir disoproxil fumarate) indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.

Development History and FDA Approval Process for Symfi

DateArticle
Mar 28, 2018Approval Mylan Introduces Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate) Triple Combo Once-Daily HIV Treatment in the U.S.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide